<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04318145</url>
  </required_header>
  <id_info>
    <org_study_id>PL-3994-701</org_study_id>
    <nct_id>NCT04318145</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects</brief_title>
  <official_title>A Multi-Center, Unblinded, Single-Arm Study to Evaluate Sex Differences in the Acute Effects of PL-3994 on Myocardial cGMP Enhancement and Hemodynamics in Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Palatin Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Palatin Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-Center, Unblinded, Single-Arm Study to Evaluate Sex Differences in the Acute Effects&#xD;
      of PL-3994 on Myocardial cGMP Enhancement and Hemodynamics in Heart Failure with Preserved&#xD;
      Ejection Fraction&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, unblinded, dose ascending, two-part pilot study involving Part A, up to 15&#xD;
      subjects for dose ascension and optimization (N=3 per dose level, up to 5 dose levels) and&#xD;
      Part B, 40 patients (n=20 women, n=20 men), with a single dose of PL-3994 after which&#xD;
      hemodynamics will be measured by pulmonary artery catheter and pulmonary artery (mixed&#xD;
      venous) and coronary sinus blood sampling will be performed to measure cGMP levels during a&#xD;
      15-minute observation period.&#xD;
&#xD;
      The objective of this study is to evaluate the acute effects of a single dose of intravenous&#xD;
      PL-3994 on hemodynamics and myocardial cGMP expression.&#xD;
&#xD;
      The following endpoints will be assessed:&#xD;
&#xD;
        -  Hemodynamics (including blood pressure, right atrial pressure, pulmonary artery&#xD;
           pressure, pulmonary capillary wedge pressure, and cardiac output)&#xD;
&#xD;
        -  Myocardial cGMP expression via coronary sinus sampling&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Part A: Single dose per subject, dose level ascension every 3 subjects. 5 dose levels are planned. An intermediate dose between planned doses may be chosen by the Sponsor/Investigator upon discussion after MTD is reached.&#xD;
Part B: Single dose, dose chosen from Part A.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Dose Ascension</measure>
    <time_frame>1 day</time_frame>
    <description>Reaching the maximum tolderated dose (MTD) as defined by meeting stopping criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Coronary Sinus Levels</measure>
    <time_frame>1 day</time_frame>
    <description>Coronary sinus levels of cGMP post PL-3994 infusion as compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part B: Blood pressure measured in mmHg</measure>
    <time_frame>1 day</time_frame>
    <description>Measured at baseline (t=0) and at t=3, 6, 9, 12, and 15 minutes after the infusion of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Heart rate measured in beats per minute</measure>
    <time_frame>1 day</time_frame>
    <description>Measured at baseline (t=0) and at t=3, 6, 9, 12, and 15 minutes after the infusion of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Right atrial pressure measured in mmHg</measure>
    <time_frame>1 day</time_frame>
    <description>Measured at baseline (t=0) and at t=3, 6, 9, 12, and 15 minutes after the infusion of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Pulmonary artery pressure measured in mmHg</measure>
    <time_frame>1 day</time_frame>
    <description>Measured at baseline (t=0) and at t=3, 6, 9, 12, and 15 minutes after the infusion of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Pulmonary capillary wedge pressure measured in mmHg</measure>
    <time_frame>1 day</time_frame>
    <description>Measured at baseline (t=0) and at t=3, 6, 9, 12, and 15 minutes after the infusion of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Cardiac output measured in L/min.</measure>
    <time_frame>1 day</time_frame>
    <description>Measured at baseline (t=0) and at t=3, 6, 9, 12, and 15 minutes after the infusion of study drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Part A: PL-3994 Dose Ascension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose ascension: up to 15 subjects with HFpEF. N = 3 per dose level, up to 5 dose levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: PL-3994 Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 40 subjects with HFpEF (20 Females, 20 Males) will receive a single dose of PL-3994.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PL-3994 Aqueous Intravenous Solution Dose Ascention</intervention_name>
    <description>Following appropriate dilution, PL-3994 will be injected intravenously by site personnel as a bolus dose followed by continuous infusion</description>
    <arm_group_label>Part A: PL-3994 Dose Ascension</arm_group_label>
    <other_name>PL-3994</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PL-3994 Aqueous Intravenous Solution Single Dose</intervention_name>
    <description>Following appropriate dilution, PL-3994 will be injected intravenously by site personnel as a bolus dose followed by continuous infusion</description>
    <arm_group_label>Part B: PL-3994 Single Dose</arm_group_label>
    <other_name>PL-3994</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject has provided written informed consent.&#xD;
&#xD;
          2. Pre- or post-menopausal female or male age &gt; 21 years&#xD;
&#xD;
          3. LVEF ≥ 45% by echocardiography within prior 6 months&#xD;
&#xD;
          4. Symptoms of HF requiring treatment with diuretics for ≥ 30 days prior to enrollment&#xD;
&#xD;
          5. Current symptoms of HF (NYHA class II-IV) at time of enrollment&#xD;
&#xD;
          6. 6. The subject has clinical indication for right heart catheterization for evaluation&#xD;
             of HFpEF&#xD;
&#xD;
          7. Negative pregnancy test in a female of childbearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A subject who meets ANY of the following exclusion criteria must not be enrolled.&#xD;
&#xD;
               1. Orthostatic hypotension, systolic blood pressure &lt;100 mm Hg, diastolic blood&#xD;
                  pressure &lt; 50 mmHg.&#xD;
&#xD;
               2. Any prior echocardiogram with LVEF &lt; 40%&#xD;
&#xD;
               3. Hemoglobin &lt; 9 g/dl&#xD;
&#xD;
               4. eGFR &lt; 30 mL/min/1.73 m2&#xD;
&#xD;
               5. Hemodynamically significant arrhythmias within prior 4 weeks&#xD;
&#xD;
               6. Acute coronary syndrome, cardiac surgery, or percutaneous coronary intervention&#xD;
                  within prior 3 months&#xD;
&#xD;
               7. Any of the following cardiac diagnoses: active myocarditis, hypertrophic&#xD;
                  cardiomyopathy, &gt; moderate regurgitant valvular disease, any valvular stenosis,&#xD;
                  restrictive cardiomyopathy (including amyloid, sarcoid, or hemochromatosis),&#xD;
                  constrictive pericarditis, complex congenital heart disease, or pulmonary&#xD;
                  arterial hypertension&#xD;
&#xD;
               8. Current need for IV inotropic medication&#xD;
&#xD;
               9. Currently taking nitrates or having stopped nitrates within 24 hours of visit&#xD;
&#xD;
              10. Currently taking antihistamines, antipsychotics, tri-cyclic antidepressants,&#xD;
                  catecholamines/related compounds, monoamine oxidase inhibitors, stimulants&#xD;
                  (including caffeine and nicotine), sympathomimetics, dopamine agonists.&#xD;
                  Additionally, medications that inhibit PDE activity will be prohibited during the&#xD;
                  study and for 5 half- lives prior to Day 1 so that cGMP measurements will not be&#xD;
                  affected&#xD;
&#xD;
              11. Currently hospitalized for HF&#xD;
&#xD;
              12. Any prior need for mechanical circulatory support&#xD;
&#xD;
              13. Previous adverse reaction to the study drug&#xD;
&#xD;
              14. Inability to comply with planned study procedures&#xD;
&#xD;
              15. Pregnant or nursing mothers&#xD;
&#xD;
              16. Participation in another study with an investigational drug or device within 30&#xD;
                  days or a biologic study within 90 days prior to signing consent.&#xD;
&#xD;
              17. Study participants must use method of birth control that has been approved by the&#xD;
                  Study Doctor and males must not donate sperm during the study and for 30 days&#xD;
                  after the last dose of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sangiv J. Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason Winters</last_name>
    <phone>609-495-2243</phone>
    <email>jwinters@palatin.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjiv J Shah, MD</last_name>
      <phone>312-695-0993</phone>
      <email>sanjiv.shah@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ryan Sisk</last_name>
      <email>r-sisk@northwestern.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>March 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure, Ejection Fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

